论文部分内容阅读
美国过敏药物顾问委员会向美国食品和药物管理局(FDA)推荐批准加洲的GtechInc公司推出的CF治疗剂Pulmozyme。该公司很可能得到FDA的认可。要把这种药物推向市场的障碍是规模放大。脱氧核糖核酸酶即将得到批准
The American Allergy Drug Advisory Board recommended to the U.S. Food and Drug Administration (FDA) approval of Pulmonaryzyme, a CF therapeutic, from GtechInc in California. The company is likely to get FDA approval. The obstacle to getting this drug to market is to scale up. DNase will be approved soon